alexa Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Evenepoel P

Abstract Share this page

Abstract Secondary hyperparathyroidism (SHPT) remains a highly prevalent and important complication in patients with chronic kidney disease (CKD). Indeed, SHPT may compromise bone health and contribute to the increased cardiovascular risks of these patients. Calcimimetic agents may help to control SHPT and to achieve the stringent mineral metabolism targets in patients with CKD stage 5D. Whether this will translate in improved patient-level outcomes remains to be demonstrated in adequately powered prospective intervention studies. These studies are currently ongoing. Additional investigations are required to define how calcimimetics fit best in the expanding armamentarium to treat SHPT. The role of vitamin D (analogs) and parathyroidectomy needs to be reevaluated in the calcimimetic era. Persistent hyperparathyroidism after successful renal transplantation may also become an important indication for therapy with calcimimetics. In patients with this complication, calcimimetics may help to improve bone health both by suppressing bone turnover and demineralization and may retard or prevent nephrocalcinosis of the graft. The evidence for using calcimimetics in CKD patients not yet on dialysis, conversely, is less straightforward. In these patients, therapy for SHPT should rather be focused on the primary trigger, i.e. the high phosphate load relative to the functional nephron mass. This article was published in Kidney Int and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version